



## Corrigendum

## Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’



Suzy Scholl<sup>a,\*</sup>, Marina Popovic<sup>b</sup>, Anne de la Rochefordiere<sup>a</sup>, Elodie Girard<sup>a</sup>, Sylvain Dureau<sup>a</sup>, Aljosa Mandic<sup>v</sup>, Katarina Koprivsek<sup>b,v</sup>, Nina Samet<sup>c</sup>, Marius Craina<sup>d</sup>, Madalin Margan<sup>d</sup>, Sanne Samuels<sup>e</sup>, Henry Zijlmans<sup>e</sup>, Gemma Kenter<sup>e</sup>, Peter Hillemanns<sup>f</sup>, Sorin Dema<sup>d</sup>, Alis Dema<sup>d</sup>, Goran Malenkovic<sup>v</sup>, Branislav Djuran<sup>b</sup>, Anne Floquet<sup>g</sup>, Delphine Garbay<sup>g</sup>, Frédéric Guyon<sup>g</sup>, Pierre Emmanuel Colombo<sup>h</sup>, Michel Fabbro<sup>h</sup>, Christine Kerr<sup>h</sup>, Charlotte Ngo<sup>i</sup>, Fabrice Lecuru<sup>i</sup>, Eleonor Rivin del Campo<sup>j</sup>, Charles Coutant<sup>k</sup>, Frédéric Marchal<sup>l</sup>, Nathalie Mesgouez-Nebout<sup>m</sup>, Virginie Fourchette<sup>a</sup>, Jean Guillaume Feron<sup>a</sup>, Philippe Morice<sup>n</sup>, Eric Deutsch<sup>n</sup>, Pauline Wimberger<sup>o</sup>, Jean-Marc Classe<sup>p</sup>, Noreen Gleeson<sup>q</sup>, Heiko von der Leyen<sup>r</sup>, Mathieu Minsat<sup>a</sup>, Coraline Dubot<sup>a</sup>, Pierre Gestraud<sup>a</sup>, Attila Kereszt<sup>s</sup>, Istvan Nagy<sup>s</sup>, Balazs Balint<sup>s</sup>, Els Berns<sup>t</sup>, Ekaterina Jordanova<sup>e</sup>, Nicolas de Saint-Jorre<sup>u</sup>, Alexia Savignoni<sup>a</sup>, Nicolas Servant<sup>a</sup>, Philippe Hupe<sup>a</sup>, Leanne de Koning<sup>a</sup>, Pierre Fumoleau<sup>a</sup>, Roman Rouzier<sup>a</sup>, Maud Kamal<sup>a</sup>

<sup>a</sup> Institut Curie, PSL Research University, Department of Drug Development and Innovation, France

<sup>b</sup> Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia

<sup>c</sup> Publica Institutul Oncologic, Republic of Moldova

<sup>d</sup> University of Medicine and Pharmacy "Victor Babeş", Romania

<sup>e</sup> Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

<sup>f</sup> Hannover Medical School, Germany

<sup>g</sup> Chirurgie onco-gynécologique and Oncology, Institut Bergonié, Centre Régional de Lutte contre le Cancer Bordeaux-Aquitaine, France

<sup>h</sup> Centre Val d'Aurelle, France

<sup>i</sup> Service de chirurgie cancérologique gynécologique et du sein, Hôpital Européen Georges Pompidou, APHP et faculté de médecine, Université Paris Descartes, France

<sup>j</sup> Department of Radiation Oncology, Tenon University Hospital, Hôpitaux Universitaires Est Parisien, Sorbonne University Medical Faculty, Paris, France

<sup>k</sup> Centre Georges François Leclerc, France

<sup>l</sup> Département de chirurgie, CRAN, UMR 7039, Université de Lorraine, CNRS, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne - CS 30519 54519, Vandoeuvre-les-Nancy Cedex, France

<sup>m</sup> Institut de cancérologie de l'Ouest – site Paul Papin (ICO) 15, Rue André Boquel, 49055 Angers, France

<sup>n</sup> Gustave Roussy, France

<sup>o</sup> Department of Gynecology and Obstetrics, Universitätsklinikum Carl Gustav Carus; an der Technischen Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany

<sup>p</sup> René Gauducheau, France

<sup>q</sup> St James/Trinity College, Ireland

<sup>r</sup> Hannover Clinical Trial Center GmbH, Germany

<sup>s</sup> SeqOmics Biotechnology Ltd, Vallalkozok utja 7, Morahalom, Hungary

<sup>t</sup> Erasmus MC, The Netherlands

<sup>u</sup> Quanticsoft, France

<sup>v</sup> Faculty of Medicine Novi Sad, University of Novi Sad, Serbia

The authors wish to clarify that the authors Aljosa Mandic, Katarina Koprivsek, and Goran Malenkovic are also affiliated with Faculty

of Medicine Novi Sad, University of Novi Sad, Serbia, as well as Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.

DOI of original article: <http://dx.doi.org/10.1016/j.ebiom.2019.03.069>.

\* Corresponding author at: Department of Drug Development and Innovation, Institut Curie, 26, rue d'Ulm, Paris 75005, France.

E-mail address: [suzy.scholl@curie.fr](mailto:suzy.scholl@curie.fr) (S. Scholl).

<https://doi.org/10.1016/j.ebiom.2020.102875>

2352-3964/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)